Pediatric Cancer

EDU 19 - PENTEC: Pediatric Normal Tissue Effects in the Clinic: An International Collaboration to Synthesize Data on Normal Tissue Radiation Dose-Volume Tolerances as Impacted by Development for Pediatric Cancer Patients

9/17/2019
4:45 PM - 6:00 PM
Location: Room W190

Session Type: Education
1.25 AMA PRA Category 1 Credits™
1.25 CAMPEP Credits
1.50 MDCB Credits

Childhood cancer cure rates approach 80%. Both radiotherapy and chemotherapy can cause debilitating or even fatal "late effects" that are critical to understand, mitigate, or prevent. Determining radiation dose constraints is particularly complicated for children in whom a mosaic of tissues develops at different rates and temporal sequences. Childhood survivors have long life expectancy and may develop treatment-induced secondary cancers and severe organ/tissue injury long after treatment. Collaborative long-term observational studies and clinical research programs for pediatric and adolescent cancer survivors provide dose response data of varying quality for follow-up periods exceeding 40 years. PENTEC (Pediatric Normal Tissue Effects in the Clinic) is a group of more than 150 physicians, physicists and epidemiologists organized into 18 organ-specific expert panels conducting a critical synthesis of existing studies aiming to (1) develop quantitative evidence based dose/volume guidelines to inform treatment planning and improve outcomes for survivors of radiation therapy for childhood cancers, (2) describe relevant physics issues specific to pediatric radiotherapy, and (3) propose dose-volume-outcome reporting standards to systematically inform future treatment guidelines. The impact of other critical contributors to normal tissue damage, including chemotherapy, surgery, stem cell transplantation and underlying genetic predispositions are also considered. In this session, we will review:

1. Relevant normal tissue complication radiation dose-response modeling issues specific to pediatrics
2. Data from several organs on radiation-associated injury according to dose, volume, and risk factors that include systemic therapies
3. Ongoing challenges (e.g. confounding therapeutic and developmental/genetic variables)
4. Recommendations for dose constraints in pediatric cancer treatment protocols.

Learning Objectives:

Presentations:

Louis Constine, MD, FACR, FASTRO

University of Rochester

Disclosure:
Employment
University of Rochester: Professor: Employee

Compensation
Childhood Cancer Survivors Study: Advisory Board: Travel Expenses;
Particle Therapy Cooperative Group-North America: Honoraria: Travel Expenses: Relationship ended 12/01/2918;
Wolters Kluwer: Honoraria

Leadership
American College of Radiology: Lymphoma Appropriateness Criteria Committee: Chair; Pediatric Normal Tissues in the Clinic: PENTEC: chair

Presentation(s):

Send Email for Louis Constine


Assets

EDU 19 - PENTEC: Pediatric Normal Tissue Effects in the Clinic: An International Collaboration to Synthesize Data on Normal Tissue Radiation Dose-Volume Tolerances as Impacted by Development for Pediatric Cancer Patients



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for EDU 19 - PENTEC: Pediatric Normal Tissue Effects in the Clinic: An International Collaboration to Synthesize Data on Normal Tissue Radiation Dose-Volume Tolerances as Impacted by Development for Pediatric Cancer Patients